Arthritis & Rheumatology Publishes the First Randomized Placebo-Controlled Study Over 52 Weeks in Non-Radiographic Axial Spondyloarthritis Showing Positive Results for CIMZIA® (certolizumab pegol)

Monday, March 11, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

-- Results from C-AXSPAND, the first 52-week placebo-controlled study in adult patients with non-radiographic axial spondyloarthritis (nr-axSpA), demonstrated the potential impact of CIMZIA® (certolizumab pegol) when added to common background medications



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store